Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Apr;45(4):e16158.
doi: 10.1111/liv.16158. Epub 2024 Nov 12.

Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study

Carine Nicolas  1 , Quentin Domas  1 , Stanislas Pol  2 , Edouard Bardou-Jacquet  3 , Véronique Loustaud-Ratti  4 , Sophie Métivier  5 , Tarik Asselah  6 , Dominique Thabut  7 , Marc Bourlière  8 , Philippe Mathurin  9 , Juliette Foucher  10 , Dominique Larrey  11 , Anne Varaut  12 , Laurent Alric  13 , François Bailly  14 , Léon Muti  1 , Benjamin Buchard  1 , Armando Abergel  1   15
Affiliations
Multicenter Study

Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study

Carine Nicolas et al. Liver Int. 2025 Apr.

Abstract

Background: Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%.

Methods and results: Here we evaluated sustained virological response at week 12 post-treatment (SVR12) in 147 HCV-GT-5 patients from 14 French university hospitals (2014-2021) treated with direct-acting antivirals (DAA) in real-life. Patients had mainly received sofosbuvir/ledipasvir ± ribavirin, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir. Overall SVR12 was 98% (144/147). Two patients experienced relapse: one was successfully retreated with the same DAAs (sofosbuvir/ledipasvir) plus ribavirin, and the other refused further DAA treatment. One patient with virological failure (sofosbuvir/velpatasvir) had received a second treatment (sofosbuvir/velpatasvir/voxilaprevir) and progressed to cure.

Conclusions: HCV-GT-5 patients treated with a DAA regimen had a 99% SVR12 in intention-to-treat (including initial therapy and retreatment) and 100% SVR12 per protocol. Sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir show very good efficacy in real-world HCV-GT-5 patients.

Keywords: direct‐acting antiviral; genotype 5; hepatitis C virus; real‐world; sustained virological response.

PubMed Disclaimer

References

    1. The Polaris Observatory HCV Collaborators, “Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modelling Study,” Lancet Gastroenterology & Hepatology 2, no. 3 (2017): 161–176.
    1. C. Henquell, A. Abergel, J. L. Bailly, and H. Peigue‐Lafeuille, “Le Virus de L'hépatite C de Génotype 5: Un Virus Rare, Une Histoire Épidémiologique Méconnue,” Virologie 15, no. 5 (2011): 286–295.
    1. S. Karatapanis, P. Tsoplou, V. Papastergiou, et al., “Hepatitis C Virus Genotyping in Greece: Unexpected High Prevalence of Genotype 5a in a Greek Island,” Journal of Medical Virology 84, no. 2 (2012): 223–228.
    1. A. Abergel, S. Ughetto, S. Dubost, et al., “The Epidemiology and Virology of Hepatitis C Virus Genotype 5 in Central France,” Alimentary Pharmacology & Therapeutics 26, no. 10 (2007): 1437–1446.
    1. Haute Autorité de Santé, “Recommandation du Collège de la Has, Pris en Charge de L'hépatite C par les Médicaments Antiviraux D'action Directe (Aa), Élargissement du Périmètre de Remboursement,” (2016), https://www.has‐sante.fr/upload/docs/application/pdf/2016‐12/recommandation_college_hepa....

Publication types

MeSH terms

LinkOut - more resources